期刊文献+

子宫内膜癌组织雌、孕激素受体测定及其临床意义 被引量:2

The measurement and the clinical significance of ER and PR in endometrial carcinoma
下载PDF
导出
摘要 目的:探讨子宫内膜癌组织雌激素受体(ER)和孕激素受体(PR)与临床病理特征的关系。方法:采用葡聚糖-活性炭吸附法(DCC法)对68例子宫内膜癌组织进行ER、PR测定,同时采用免疫组化法对其中30例进行ER、PR检测。结果:DCC法检测ER、PR的阳性率分别为79·4%和77·9%,免疫组化法均为86·7%。两种测定方法比较,ER与PR的总符合率分别为82·4%和85·7%。免疫组化法可在DCC法基础上进一步明确组织来源。ER、PR水平与组织学分级呈负相关。组织类型中腺癌(包括乳头状腺癌)与腺棘癌的ER、PR水平高于其他癌。ER水平与肥胖呈正相关。结论:ER、PR水平与组织学分级、组织学类型均反映了子宫内膜癌的生物学行为,ER、PR的测定对估计预后和临床选择激素治疗具有重要意义。 Objective:To study estrogen receptor (ER) and progesterone receptor (PR) expression status in endometrial carcinoma and their relations with clinical and pathological characteristics. Methods : ER and PR expression status in endometrial carcinoma in 68 cases were measured using Dextran Coated Charcoal (DCC). Among 30 of these cases, immunohistochemistry method was also used to measure the ER and PR expression status. Results:Using DCC,the positive rate of ER and PR were 79.4% and 77.9% respectively, when using immunohistochemistry method, the positive rate were both 86.7%. We compared the two methods and found that : the general coincidence rate of ER and PR were 82.4% and 95.7% respectively, immunohistochemistry method could further confirm the histological origin on the base of DCC method. ER and PR status were negatively correlated with histological grading. Among the histological subtypes, ER and PR status were higher in adenocarcinoma (including papillary adenocarcinoma) and adenoacanthoma of endometrium than other subtypes. ER status was positively correlated with obesity. Conclusion:ER and PR status, histological grading, and histological subtypes could reflect the biological behavior of endometrial carcinoma. The measurement of ER and PR status is of important significance in predicting prognosis and in choosing patients that can benefit from hormonal therapy.
出处 《临床肿瘤学杂志》 CAS 2006年第10期772-774,共3页 Chinese Clinical Oncology
关键词 雌激素受体(ER) 孕激素受体(PR) 子宫内膜癌 Estrogen receptor (ER) Progesterone receptor (PR) Endometrial carcinoma
  • 相关文献

参考文献5

二级参考文献18

  • 1刘尚廉.乳腺癌雌激素受体的酶联雌二醇组化标记法[J].肿瘤,1986,6(3):104-106.
  • 2韩守威,华西医科大学学报,1989年,20卷,253页
  • 3杨泽仁,中华妇产科杂志,1988年,23卷,283页
  • 4Vaskivuo TE, Stenback F, Karhumaa P, et al. Apoptosis and apoptosis-related proteins in human endometrium[J]. Mol Cell Endocrinol, 2000, 165: 75-83.
  • 5Chen Y, Sato M, Fujimura S, Expression of Bcl-2, Bax, and p53 protein in carcinogenesis of squmous cell lung cancer [J].Anticancer Res, 1999, 19: 1351-1356.
  • 6Sakuragi N, Salah-eldin AE, Watari H. Bax, Bcl-2, and p53expression in endometrial cancer [J]. Gynecol Oncol, 2002, 86:288-296.
  • 7Morsi HM, Leers MP, Jager W,et al. The pattern of expression of an apoptosis-related CK-18 neoepitope, the bcl-2 protooncogene, and the Ki67 proliferation marker in normal,hyperplastic, and malignant endometrium [J]. Int J Gynecol Pathol, 2000, 19: 118-126.
  • 8Herderson GS, Brown KA, Perkins KA, et al . Bcl-2 is downregulated in atypical endometrial hyperplasia and adenocarcinoma [J]. Mod Pathol, 1996, 9: 430-438.
  • 9Taskin M, Lallas TA, Barber HR, et al. Bcl-2 and p53 in endometrial adenocarcinoma [J]. Mod Pathol, 1997, 10 (7):728-734.
  • 10DiSaia PJ, Creasman WT, Boronow RC, et al. Risk factors and recurrent patterns in Stage Ⅰ endometrial cancer [J]. Am J Obstet Gynecol, 1985, 151: 1009-1015.

共引文献36

同被引文献28

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部